摘要
目的探讨阿立哌唑与利培酮用于精神分裂症治疗的差异分析。方法抽取我院2017年4月至2020年6月60例精神分裂症患者,根据抽签法分为阿立哌唑组与利培酮组,每组各30例,对比临床疗效。结果两组治疗总有效率比较无意义(P> 0.05),但阿立哌唑组不良反应低于利培酮组(P <0.05);治疗后阿立哌唑组阴性与良性症状量表(PANSS)各维度评分均低于利培酮组(P <0.05);治疗后阿立哌唑组认知功能评分、生活质量评分均高于利培酮组(P <0.05)。结论阿立哌唑治疗精神分裂症效果,与利培酮比较相对较好,不良反应较小,可缓解患者病情,提高认知功能,改善生活质量,值得推广。
Objective To investigate the difference between aripiprazole and risperidone in the treatment of schizophrenia. Methods 60 patients with schizophrenia in our hospital from April 2017 to January 2018 were selected and divided into aripiprazole group and risperidone group by lottery, with 30 patients in each group for comparison of clinical efficacy. Results The total effective rate of the two groups was insignificant(P >0.05), but the side effect of aripiprazole group was lower than that of risperidone group(P <0.05). The negative and benign symptom scale(PANSS) of aripiprazole group was lower than that of risperidone group(P <0.05). After treatment, the scores of cognitive function and quality of life in aripiprazole group were higher than those in risperidone group(P <0.05). Conclusion The effect of aripiprazole in the treatment of schizophrenia is relatively better than risperidone, with less toxic and side effects. It can alleviate the condition of patients, improve their cognitive function, and improve the quality of life, which is worthy of promotion.
作者
鲁杰
廖细梅
LU Jie;LIAO Xi-mei(Department of Psychiatry,Xiaogan Social Welfare and Medical Rehabilitation Center,Xiaogan 432000,China)
出处
《中国医药指南》
2020年第7期16-18,共3页
Guide of China Medicine
